FASN and cancer: In contrast to the off-target effects reported with many anticancer drugs that target genes required for cancer proliferation in a cell-autonomous manner [98], we previously found that the efficacy of the FASNi TVB-3166 was largely prevented by CRISPR/Cas9-driven FASN KO.